More individual markers are necessary for patients with acute myeloid leukemia (AML). Does cytomorphology or cytogenetics define the biological entity?

Leukemia

Volumn 10, Issue SUPPL. 3, 1996, Pages

  Haferlach, T ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Acute myeloid leukemia; Cytogenetic; Cytomorphology; Prognostic factors

Indexed keywords

CELL MARKER; CYTARABINE; DAUNORUBICIN; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; CELL STRUCTURE; CONFERENCE PAPER; CYTOGENETICS; DATA ANALYSIS; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL;

EID: 0029802002     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposal for the classification of the acute leukemias. Br J Haematol 1976; 33: 451-458.
2. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. A variant form of acute hypergranular promyelocytic leukemia (M3). Br J Haematol 1980; 44: 169-170.
3. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 626-629.
4. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton G, Gralnick HR, Sultan C. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). Ann Int Med 1985; 103: 460-462.
5. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). Br J Haematol 1991; 78: 325-329.
6. Berger R, Bernheim A, Ochoa-Noguera ME, Daniel MT, Valensi F, Sigaux F, Flandrin G, Boiron M. Prognostic significance of the chromosomal abnormalities in acute nonlymphocytic leukemia: a study of 343 patients. Cancer Genet Cytogenet 1987; 28: 293-299.
7. Berger R, Flandrin, G, Bernheim A, Le Coniat M, Vecchione D, Pacot A, Derrè J, Daniel M-T, Valensi F, Sigaux F, Ochoa-Noguera ME. Cytogenetic studies on 519 consecutive nonlymphocytic leukemias. Cancer Genet Cytogenet 1987; 29: 9-21.
8. Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1984; 11: 259-350.
9. Arthur DC, Berger R, Golomb HM, Swansbury GJ, Reeves BR, Alimena G, Van Den Berghe H, Bloomfield CD, De la Chappelle A, Dewald G, Garson OM, Hagemeijer A, Kaneko Y, Mitelman F, Pierre RV, Ruutu T, Sakurai M, Lawler SD, Rowley JD. The clinical significance of karyotype in acute myelogenous leukemia. Sixth International Workshop on Chromosomes in Leukemia, London 1987. Cancer Genet Cytogenet 1989; 40: 203-216.
10. Keating MJ, Cork A, Broch Y, Smith T, Waltes RS, McCredie KB, Trujillo J, Freireich EJ. Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leukemia Res 1987; 11(2): 119-133.
11. Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989; 73: 263-270.
12. Berger R, Bernheim A, Daniel M-T, Valensi F, Sigaux F, Flandrin C. Cytologic characterization and significance of normal karyotypes in t(8;21) acute myeloblastic leukemia. Blood 1982; 59: 171-178.
13. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukemia. Lancet 1977; i: 549-550.
14. Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia: a unique cytogenetic-clinicopathological association. N Engl J Med 1983; 309: 630-636.
15. Büchner T, Hiddemann W, Schaefer UW, Löffler H, Maschmeyer G, Ludwig W-D, Aul C, Lathan B, Heinecke A. Combined effect of early intensification and prolonged post-remission chemotherapy in patients with AML. Leukemia 1992; 6(Suppl 4): 68-70.
16. Büchner T, Hiddemann W, Wörmann B, Heinecke A, Sauerland MC, Fonatsch C, Becher R, Hossfeld D, Goasguen J, Löffler H, Schaefer UW. Factors determining therapeutic outcome in patients with AML. Blood 1993; 82 (Suppl 11): 754.
17. Büchner T, Hiddemann W, Löffler H, Goasguen J, Bennett J, Gassmann W, Haferlach T, Fonatsch C, Becher R, Hossfeld D, Sauerland C, Heinecke A. Prognostic factors in AML (AMLCG results). Ann Hematol 1995; 70 (Suppl 11): A110.
18. Keating MJ, Smith TL, Gehan EA, McCredie KB, Bodey GP, Freireich EJ. A prognostic factor analysis for the use in development of predictive models for response in adult acute leukemia. Cancer 1982; 50: 457-465.
19. Estienne MH, Fenaux P, Preudhomme C, Lai JL, Zandecki M, Lepelley P, Cosson A. Prognostic value of dysmyelopoietic features in de novo acute myeloid leukaemia: a report on 132 patients. Clin Lab Haemat 1990; 12: 57-65.
20. Degos L, Dombret H, Chomienne C, Daniel M-T, Miclea J-M, Chastang C, Castaigne S, Fenaux P. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85: 2643-2653.
21. Büchner T, Urbanitz D, Hiddemann W, Rühl H, Ludwig W-D, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G, Nowrousian MR, König HJ, Walter M, Wendt FC, Sodomann H, Hossfeld DK, von Paleske A, Löffler H, Gassmann W, Hellriegel K-P, Fülle HH, Lunscken Ch, Emmerich B, Pralle H, Pees HW, Pfreundschuh M, Bartels H, Koeppen K-M, Schwerdtfeger R, Donhuijsen-Ant R, Mainzer K, Bonfert B, Köppler H, Zurborn K-H, Ranft K, Thiel E, Heinecke A. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985; 3: 1583-1589.
22. Schoch C, Haase D, Büchner Th, Freund M, Link H, Löffler H, Haferlach T, Fonatsch Ch. Secondary chromosome aberrations in acute myeloid leukemia with t(8;21 )(q22;q22) or inv(16)(p13 q22). Med Gen 1995; 7/2: 197.
23. Haferlach T, Bennett JM, Löffler H, Gassmann W, Andersen JW, Tuzuner N, Cassileth PA, Fonatsch C, Schoch C, Schlegelberger B, Becher R, Thiel E, Ludwig W-D, Sauerland MC, Heinecke A, Büchner T for the AML Cooperative Group and ECOG. Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. Leukemia and Lymphoma (in press)
24. Bernheim A for the Groupe Français de Cytogénétique Hématologique. Acute myelogenous leukemia with an 8;21 translocation. A report on 148 cases from the Groupe Français de Cytogénétique Hématologique. Cancer Genet Cytogenet 1990; 44: 169-179.
25. Marosi C, Köller U, Koller-Weber E, Schwarzinger I, Schneider B, Jäger U, Vahls P, Nowotny H, Pirc-Danoewinata H, Steger G, Kreiner G, Wagner B, Lechner K, Lutz D, Bettelheim P, Haas OA. Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. Cancer Genet Cytogenet 1992; 61: 14-25.
26. Yunis JJ, Brunning RD, Howe RB, Lobell M. High-resolution chromosomes as an independent prognostic indicator in adult acute nonlymphocytic leukemia. N Engl J Med 1984; 311: 812-818.
27. Yunis JJ, Lobell M, Arnesen MA, Oken MM, Mayer MC, Rydell RE, Brunning RD. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol 1988; 68: 189-194.
28. Fenaux P, Preudhomme C, Lay JL, Morel P, Beuscart R, Bauters F. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases. Br J Haematol 1989; 73: 61-67.
29. Samuels BL, Larson RA, Le Beau MM, Daly KM, Bitter MA, Vardiman JW, Barker CM, Rowley JD, Golomb HW. Specific chromosomal abnormalities in acute nonlymphoblastic leukemia correlate with drug susceptibility in vivo. Leukemia 1988; 2: 79-83.
30. Haferlach T, Gassmann W, Löffler H, Jürgensen C, Noak J, Ludwig W-D, Thiel E, Haase D, Fonatsch C, Becher R, Schlegelberger B, Nowrousian MR, Lengfelder E, Eimermacher H, Weh HJ, Braumann D, Maschmeyer G, Koch P, Heinecke A, Sauerland MC, Büchner Th. Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. Ann Hematol 1993; 66: 165-170.
31. Head DR, Kopecky KJ, Willman C, Appelbaum FR. Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience. Leukemia 1994; 8 (Suppl 2): S38-41.
32. Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M, Spier C, Hanson C, Bitter M, Braziel R, Mills G, Welborn J, Williams W, Hewlett J, Willman C, Appelbaum FR. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 1995; 86: 1717-1728.
33. Rodeghiero F, Avvisati C, Castaman C, Barbui T, Mandelli F. Early death and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GINEMA retrospective study in 268 consecutive patients. Blood 1990; 75: 2112-2117.
34. Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 1989; 73: 1116-1122.
35. Tezcan H, Barnett MJ, Bredeson CN, Reece DE, Shephard JD, Dalal BI, Horsman DE, Klingemann H-G, Nantel SH, Spinelli JJ, Sutherland HJ, Phillips GL. Treatment of acute promyelocytic leukemia in paients presenting at Vancouver General Hospital from 1983 to 1992. Leukemia and Lymphoma 1995; 16: 436-444.
36. Schoch C, Büchner Th, Freund M, Link H, Bartels H, Haferlach T, Löffler H, Fonatsch Ch. Fifty-six cases of acute myeloid leukemia with inversion (16)(p13q22): do additional chromosomal aberrations influence prognosis? Ann Hematol 1995; 70 (Suppl 11): A113.
37. Plantier-Colcher I, Lai JL, Wattel E, Bauters F, Fenaux P. inv(16) may be one of the only 'favorable' factors in acute myeloid leukemia: a report on 19 cases with prolonged follow-up. Leuk Res 1994; 18(12): 885-888.
38. Larson RA, Williams SF, Le Beau MM, Bitter MA, Vardiman JW, Rowley JD. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood 1986; 68: 1242.
39. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958; 53: 457-481.
40. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard S, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1-39.
41. Haferlach T, Löffler H, Gassmann W, Schoch R, Fonatsch C, Schoch C, Schlegelberger B, Ludwig W-D, Becher R, Thiel E, Heinecke A, Sauerland MC, Büchner T. AML M4Eo with pericentric inversion 16 is a favorable subtype of acute myeloid leukemia: Results of 65 patients treated in the AMLCG-trial. Blood 1995; 86 (Suppl 1): A3034.
42. Haferlach T, Bennett JM, Löffler H, Gassmann W, Andersen JW, Tuzuner N, Cassileth PA, Fonatsch C, Schlegelberger B, Thiel E, Ludwig W-D, Sauerland MC, Heinecke A, Büchner T for AML Cooperative Group and ECOG. Cytomorphology results and dysplastic features as prognostic factors in 41 cases with acute myeloid leukemia (AML) and the translocation (8;21). Leuk Res 1994; 18 (Suppl): 45.
43. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, Mcintyre OR, Frei E III for the CALGB. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl Med 1994; 331: 896-903.
44. Haferlach T, Löffler H, Gassmann W, Schoch R, Fonatsch C, Schoch C, Schlegelberger B, Ludwig W-D, Thiel E, Becher R, Heinecke A, Sauerland MC, Büchner T. Trilineage dysplasia (TLD) is correlated with a bad prognosis in de novo acute myeloid leukemia (AML): first results of a prospective study from the German AMLCG-trial. Blood 1995; 86 (Suppl 1): A165.
45. Mertelsmann R, Thaler HT, To L, Gee TS, Mcenzie S, Schauer P, Friedman A, Arlin Z, Cirrincione C, Clarkson B. Morphological classification, responses to therapy, and survival in 268 patients with acute nonlymphoblastic leukemia. Blood 1980; 56: 773-781.
46. Swirsky DM, de Bastos M, Parish SE, Rees JKH, Hayhoe FGJ. Features affecting outcome during remission induction of acute myeloid leukaemia in 619 adult patients. Br J Haematol 1986; 64: 435-453.